Sanofi reported stronger than expected third-quarter profit on Friday, boosted by demand for blockbuster asthma drug Dupixent ...

Sanofi on Friday reported third-quarter profit that beat forecasts, boosted by demand for blockbuster asthma drug Dupixent, ...

Novavax, Inc. (NASDAQ:NVAX) is one of the top long-term biotechnology stocks to buy. On October 24, Cantor Fitzgerald ...

The MoU supports Saudi Vision 2030 and the National Transformation Program’s focus on localizing healthcare manufacturing ...

Dupixent’s Q3 sales increased by 26.2%, breaking through the €4bn ceiling for the first time in a single quarter.

Sanofi has dropped its respiratory syncytial virus (RSV) vaccine for toddlers after the candidate underperformed in a phase 3 ...

Sales of Sanofi’s COVID-19 and flu vaccines fell 17% in the third quarter amid declining vaccination rates and pricing ...

Over the last 13 months, Sanofi and Regeneron have revved up the momentum for Dupixent, gaining three new indications for the ...

GSK raised its 2025 sales and earnings forecasts on Wednesday as its speciality HIV and cancer drugs posted double digit ...

Sanofi SNY reported third-quarter 2025 adjusted earnings of $1.70 per American depositary share, which beat the Zacks ...

Shares rose after a jump in sales of the blockbuster Dupixent drug and robust pharmaceutical launches delivered higher ...

Sanofi’s Q3 saw total revenues rise 7% CER, with Dupixent contributing over €4 billion for the first time. Click here to read ...